Skip to content

Clinical trials

Microscopic Polyangiitis trials in the United Kingdom

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Microscopic Polyangiitis Country / region: United Kingdom Clear all

16 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20032
20071
20101
20112
20121
20133
20192
20201
20241
20251

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed5
Unknown status5
Terminated4
Active, not recruiting2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Cambridge University Hospitals NHS Foundation Trust3
Novartis Pharmaceuticals2
University of Oxford2
Assistance Publique - Hôpitaux de Paris1
Charite University, Berlin, Germany1
Guy's and St Thomas' NHS Foundation Trust1
Human Genome Sciences Inc., a GSK Company1
Imperial College London1
InflaRx GmbH1
University Hospital Birmingham NHS Foundation Trust1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Microscopic Polyangiitis16
Granulomatosis with Polyangiitis15
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis8
Vasculitis8
Churg-Strauss Syndrome6
Systemic Vasculitis3
Polyarteritis Nodosa2
Takayasu Arteritis2
Autoimmune Diseases1
Giant Cell Arteritis1

Trials

Showing 51 to 16 of 16. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.